BRAIN BIOTECNA O.N. news, videos and press releases - Page 2
For more news please use our advanced search feature.
BRAIN BIOTECNA O.N. - More news...
BRAIN BIOTECNA O.N. - More news...
- EQS-News: Resolutions of the Annual General Meeting 2023 on the Financial Year 2021/2022 of BRAIN Biotech AG
- EQS-News: Capital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion
- EQS-News: BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting
- EQS-News: BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment
- EQS-Adhoc: BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères
- EQS-News: BRAIN Biotech AG reports record figures in fiscal year 2021/22 − despite challenging geopolitical environment
- EQS-News: BRAIN Biotech AG: BRAIN Group's Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform
- EQS-Adhoc: BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing)
- EQS-News: BRAIN Biotech AG: Key Leadership Appointments at BRAIN Biotech AG, Zwingenberg Site
- EQS-News: BRAIN Biotech AG: MP Beteiligungs-GmbH Increases Stake in BRAIN Biotech AG
- EQS-News: BRAIN Biotech and Bonumose collaborate on enzymes for the production of rare monosaccharides
- EQS-News: Change in the Executive Management Board of BRAIN Biotech AG, genome editing activities established under the Akribion Genomics brand
- EQS-News: BRAIN Biotech AG sells subsidiary L.A. Schmitt to a URI group company
- DGAP-News: BRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting
- DGAP-News: BRAIN Biotech publishes first ESG and Sustainability Report
- DGAP-News: BRAIN Biotech AG: Prof. Dr. Bernhard Hauer leaves Supervisory Board of BRAIN Biotech AG for personal reasons
- DGAP-News: BRAIN Biotech AG: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting
- DGAP-News: BRAIN Biotech AG: Successful Genome Editing in Mammalian Cells with BRAIN-Metagenome-Cas (BMC), BRAIN-Engineered-Cas (BEC)
- DGAP-Adhoc: BRAIN Biotech AG: Successful Genome Editing Activity in Mammalian Cells with BRAIN-Metagenome-Cas (BMC), BRAIN-Engineered-Cas (BEC)
- DGAP-News: BRAIN Biotech AG: Resolutions of the Annual General Meeting for the Fiscal Year 2020/2021 of BRAIN Biotech AG
- DGAP-News: BRAIN Biotech AG: Very Dynamic Start into the Fiscal Year 2021/22, 3M Reporting
- DGAP-News: BRAIN Biotech and Formo: Strategic partnership of European biotech experts for the production of animal-free milk protein
- DGAP-News: BRAIN Group significantly expands its food enzyme business with the acquisition of Breatec B.V. and Comix business
- DGAP-Adhoc: BRAIN Biotech AG: BRAIN Group expands its food enzyme business with the acquisition of a majority of Breatec B.V. and Comix
- DGAP-News: BRAIN Biotech AG publishes Annual Report for FY 2020/21
- DGAP-News: BRAIN Biotech AG: BRAIN-Engineered-Cas (BEC) Considered a Patentable Technology
- DGAP-Adhoc: BRAIN Biotech AG: BRAIN-Engineered-Cas (BEC) Considered a Patentable Technology
- DGAP-News: BRAIN Biotech AG: Additional Genome Editing Nuclease: BRAIN-Metagenome-Cas 01 (BMC01)
- DGAP-Adhoc: BRAIN Biotech AG: Additional Differentiated Genome-Editing Nuclease: BRAIN-Metagenome-Cas 01 (BMC01)
- DGAP-News: BRAIN Biotech AG: BRAIN and SAMS apply BEC gene-editing technology to Omega-3 Compounds from Marine Organisms
